Specific Gene Expression Predicts Risk for Prostate Cancer(5/9/2008) Researchers from Barcelona, Spain, have reported that expression of the PTOV1 (prostate tumor overexpressed-1) gene helps predict the likelihood of the development of prostate cancer among men with high-grade prostatic intraepithelial neoplasia (HG-PIN). These results were recently published in the May 2008 issue of Clinical Cancer Research.
Pulsed Angiolytic Laser Therapy Effective for Laryngeal Cancer(5/9/2008) Researchers from Massachusetts General Hospital have reported promising results of treatment of early-stage laryngeal cancer with a new laser called the pulsed angiolytic KTP. The details of this Phase II study were presented at the 2008 meeting of the Broncho-Esophagological Association meeting in Orlando, Florida, on May 1. Details of this study are available on the Massachusetts General Web site, and a definitive report will be published in the July 2008 issue of the Annals of Otology, Rhinology and Laryngology.
Highlights from the 2007 San Antonio Breast Cancer Symposium (SABCS) - CME This independent conference coverage provides expert updates in the management of breast cancer from Dr. Lee Schwartzberg, Dr. Lori Goldstein, Dr. Georgiana Ellis, and more. Continuing Medical Education credits will be available soon. More
Click here for an expert interview with Dr. Lee Schwartzberg of the West Clinic on Highlights and Clinical Impact of the data from the 2007 SABCS on metastatic breast cancer.
Highlights from the 49th Annual Meeting of the American Society of Hematology (ASH) - CME This independent conference coverage provides expert updates in the management of Immune Thrombocytopenic Purpura, Chronic Myeloid Leukemia, Myelodysplastic Syndromes, and other hematologic malignancies, authored by Hagop Kantarjian, MD; Mikkael Sekeres, MD; and Charles Abrams, MD. Continuing Medical Education credits will be available soon. More
Highlights from the 12th World Conference on Lung Cancer- CME This independent conference coverage provides expert updates in the management of non-small cell lung cancer, small cell lung cancer and malignant pleural mesothelioma, authored by Chandra Belani, MD, Penn State Cancer Center, Hershey, PA;David Spigel, MD, The Sarah Cannon Research Institute, Nashville, TN; andDavid Jackman, MD, Dana-Farber Cancer Institute, Boston, MD. More
New Agents for the Treatment of Lymphoma: A Review of the LiteratureCME Interactive Literature Review Fredrick B. Hagemeister, MD, The Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
With Comments by John P. Leonard, MD, Associate Professor of Medicine, Weill Medical College of Cornell University; Clinical Director, New York-Cornell Center for Lymphoma and Myeloma in New York City Release date: March 30, 2007.
Case Study in Refractory Anemia-CME Interactive Case Study Ravi Vij, MD, Washington University in St. Louis School of Medicine. Release date: February 1, 2007.
Treanda® Approved by FDA for Initial Treatment of CLL(3/25/2008) On March 20, 2008, the U.S. Food and Drug Administration (FDA) approved IV Treanda® (bendamustine) for initial treatment of chronic lymphocytic leukemia (CLL). The results were based on data from a randomized multicenter trial that were presented at the 2007 meeting of the American Society of Hematology (ASH), December 8-11, in Atlanta, Georgia.
Medicare and Medicaid Guidelines for Epoetin and Darbepoetin for Non-Renal Indications(8/3/2007) The Centers for Medicare and Medicaid Services (CMS) has published new guidelines for the use of erythropoiesis stimulating agents (ESAs) for non-renal indications.These guidelines are important since they guide reimbursement for epoetin (Procrit®, Epogen®) and darbepoetin (Aranesp®) in cancer patients.
Patient Home
